Targeting Alternative Splicing as Adjunctive Treatment in EML4-ALK v3a/b+ NSCLC: Knowing Our Socratic Paradox and Learning From Spinal Muscular Atrophy-Reference-Cited by-同舟云学术

Targeting Alternative Splicing as Adjunctive Treatment in EML4-ALK v3a/b+ NSCLC: Knowing Our Socratic Paradox and Learning From Spinal Muscular Atrophy

Published:2022-02 Issue:2 Volume:17 Page:182-185
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Nagasaka Misako,Ou Sai-Hong Ignatius

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference21 articles.

1. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

2. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer;Choi;Cancer Res,2008

3. Song Z, Lian S, Mak S, et al. Deep RNA sequencing revealed fusion junctional heterogeneity may predict crizotinib treatment efficacy in ALK-rearranged NSCLC. J Thorac Oncol. 2022;17:264–276.

4. Clinical characteristics and sequence complexity of anaplastic lymphoma kinase gene fusions in Chinese lung cancer patients;Tian;Lung Cancer,2017

5. Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC;Zhang;Lung Cancer,2021

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC;Cancer Research Communications;2024-03-14

2. Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver;Lung Cancer: Targets and Therapy;2024-02

3. Plasma Genotyping From the CROWN, ALTA-1L, and ALEX Trials: Can We Speak With One Voice on What to Test, How to Test, When to Test, and for What Purpose?;Journal of Thoracic Oncology;2023-11

4. CROWN 2022 Second Interim Updates: When Will Be the Coronation of Lorlatinib?;Journal of Thoracic Oncology;2023-02

5. Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer;Cancers;2022-07-15